Citations

Clear

3138 citation(s) found for "Smith, AM".

O1‐13‐03: The Mild Behavioral Impairment Checklist (MBI‐C): a New Rating Scale for Neuropsychiatric Symptoms as Early Manifestations of Neurodegenerative Disease
Ismail, Zahinoor , Cieślak, Alicja , Gauthier, Serge , Herrmann, Nathan , Kanji, Jamila, Mortby, Moyra E. , Onyike, Chiadikaobi, Ortiz, Luis Agüera, Rosenberg, Paul B. , Smith, Gwenn S. , Sultzer, David L. , Brodaty, Henry , Fischer, Corinne Eleanor , Geda, Yonas E. , Lanctôt, Krista L. , Miller, David, Onyike, Chiadi , Smith, Eric Edward , Cummings, Jeffrey L. , Lyketsos, Constantine G.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_4 | Pages: No page available

10.1016/j.jalz.2016.06.366 Get It

IC‐P‐173: Utility of PMOD Image Quantification Software for Processing [11C]PIB and [18F]Flutemetamol Images for SUVR Quantitation on The Centiloid Scale
Smith, Adrian, Lowe, Val J. , Battle, Mark R , Buckley, Christopher J. , Laere, Koen Van , Vandenberghe, Rik

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_2 | Pages: No page available

10.1016/j.jalz.2016.06.204 Get It

F5‐02‐03: BDNF VAL66MET Moderates Cognitive Impairment, Neuronal Dysfunction and TAU in Preclinical Autosomal Dominant Alzheimer's Disease
Fagan, Anne M. , Benzinger, Tammie Lee Smith, Ricardo, Allegri, Chhatwal, Jasmeer P. , Farlow, Martin R. , Graff‐Radford, Neill R. , Laske, Christoph , Ringman, John M. , Salloway, Stephen , Lim, Yen Ying , Hassenstab, Jason , Cruchaga, Carlos , Goate, Alison , Benzinger, Tammie L.S. , Maruff, Paul , Snyder, Peter J. , Masters, Colin L. , Allegri, Ricardo , Xiong, Chengjie , McDade, Eric , Rossor, Martin N. , Schofield, Peter William , Holtzman, David M. , Morris, John C. , Bateman, Randall J.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_7 | Pages: No page available

10.1016/j.jalz.2016.06.689 Get It

O2‐03‐02: are White Matter Hyperintensities a Core Feature of Alzheimer’s Disease or Just a Reflection of Amyloid Angiopathy? Evidence From the Dominantly Inherited Alzheimer Network (DIAN)
Zimmerman, Molly E. , Viqar, Fawad, Narkhede, Atul, Benzinger, Tammie Lee Smith, Marcus, Daniel S., Cairns, Nigel J. , Buckles, Virginia, Saykin, Andy J., Ringman, John M. , Ryan, Natalie S. , Förster, Stefan , Laske, Christoph , Salloway, Stephen , Correia, Stephen , Weiner, Michael W. , Mayeux, Richard , Lee, Seonjoo , Tosto, Giuseppe , Goate, Alison , Fox, Nick C. , Holtzman, David M. , Ghetti, Bernardino , McDade, Eric , Martins, Ralph N. , Saykin, Andy J., Masters, Colin L. , Schofield, Peter R. , Sperling, Reisa Anne , Bateman, Randall J. , Morris, John C. , Jack, Clifford R. , Brickman, Adam M.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_4 | Pages: No page available

10.1016/j.jalz.2016.06.406 Get It

Kidney function and appropriateness of device therapies in adults with implantable cardioverter defibrillators
Szpiro, Adam A. , Masoudi, Frederick A. , Greenlee, Robert T. , Smith, David H. , Magid, David J. , Gurwitz, Jerry H. , Tabada, Grace H., Sung, Sue Hee, Dighe, Ashveena , Garcia‐Montilla, Romel , Hammill, Stephen C., Hayes, John, Kadish, Alan H. , Sharma, Param , Varosy, Paul D. , Vidaillet, Humberto, Go, Alan S. , Hammill, Stephen, Bansal, Nisha , Reynolds, Kristi , Cassidy‐Bushrow, Andrea E.

Mayo Clinic

Heart | October 14, 2016 | Volume: 103 | Issue: 7 | Pages: 529-537

10.1136/heartjnl-2016-309842 | PMID 27742796 Get It

Objective Patients with chronic kidney disease (CKD) have higher risk of sudden cardiac death; however, they may not receive implantable cardioverter defibrillators (ICDs), in part due to higher risk of complications. We evaluated whether CKD is associated with greater risk of device-delivered shocks/antitachycardia pacing (ATP) therapies among patients receiving a primary prevention ICD. Methods We studied participants in the observational Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter Defibrillators. CKD was defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. Outcomes included all delivered shocks/ATPs therapies and type of shock/ATP therapies (inappropriate or appropriate, determined by physician adjudication) within the 3 years. We evaluated the associations between CKD and time to first device therapy, burden of device therapy, and inappropriate versus appropriate device therapy, adjusting for demographics, comorbidity, laboratory values and medication use. Results Among 2161 participants, 1066 (49.3%) had CKD (eGFR 44±11 mL/min/1.73 m2) at ICD implantation. During mean of 2.26±0.89 years, 9.8% and 18.5% of participants had at least one inappropriate and appropriate shock/ATP therapies, respectively. CKD was not associated with time to first shock/ATP therapies (adjusted HR 0.87, 95% CI 0.73 to 1.05), overall burden of shock/ATP therapies (adjusted relative rate 0.93, 95% CI 0.74 to 1.17) or inappropriate versus appropriate shock/ATP therapies (adjusted relative risk 0.88, 95% CI 0.68 to 1.14) compared with not having CKD. Conclusions In adults receiving a primary prevention ICD, mild-to-moderate CKD was not associated with the timing, burden or appropriateness of subsequent device therapy. Potential concern for inappropriate ICD-delivered therapies should not preclude ICDs among eligible patients with CKD.
Responsiveness of 8 Patient‐Reported Outcomes Measurement Information System (PROMIS) measures in a large, community‐based cancer study cohort
Moinpour, Carol M. , Potosky, Arnold L. , Lobo, Tania , Hahn, Elizabeth A. , Hays, Ron D. , Cella, David , Keegan, Theresa H.M. , Paddock, Lisa E. , Stroup, Antoinette M. , Eton, David T. , Jensen, Roxanne E. , Smith, Ashley Wilder , Wu, Xiao‐Cheng

Mayo Clinic

Cancer | October 11, 2016 | Volume: 123 | Issue: 2 | Pages: 327-335

10.1002/cncr.30354 | PMID 27696377 Get It

BACKGROUND The Patient‐Reported Outcomes Measurement Information System (PROMIS) was a National Institutes of Health‐funded initiative to develop measures of symptoms and function. Responsiveness is the degree to which a measure can detect underlying changes over time. The objective of the current study was to document the responsiveness of 8 PROMIS measures in a large, population‐based cancer cohort. METHODS The Measuring Your Health study recruited 2968 patients who were diagnosed with 1 of 7 cancers between 2010 and 2012 through 4 Surveillance, Epidemiology, and End Results registries. Participants completed a baseline survey (6‐13 months after diagnosis) and a 6‐month follow‐up survey. Changes in 8 PROMIS scores were compared with global ratings of transition, changes in performance status, and clinical events. RESULTS Measures were responsive to 6‐month declines and improvements in performance status with small to large effect sizes (ES) (Cohen d = 0.34‐0.71; P < .01). Mean changes and effect sizes were larger for participants who reported declines compared with those who reported improvements. Small‐to‐medium ES were observed in patients who reported being “a little” worse (d = 0.31‐0.56), and medium‐to‐large ES were observed in those who reported being “a lot” worse (d = 0.53‐0.72). Hospitalized participants reported significant score increases, resulting in worsening of pain (d = 0.51), fatigue (d = 0.35), and depression (d = 0.57; all P < .01). Cancer recurrence and progression were associated with smaller increases in pain, fatigue, and sleep disturbance (d = 0.22‐0.27). CONCLUSIONS The current results indicated that all 8 PROMIS measures were sensitive to patient‐perceived worsening and improvement and to major clinical events. These findings will be able to inform the design and interpretation of future research studies and clinical initiatives administering PROMIS measures. Cancer 2017;123:327–335. © 2016 American Cancer Society .
The Effect of In-School Saccadic Training on Reading Fluency and Comprehension in First and Second Grade Students
Starling, Amaal J. , Wethe, Jennifer V. , Messner, Leonard V., Master, Christina L. , Halker-Singh, Rashmi B., Vargas, Bert B., Bogle, Jamie M. , Mandrekar, Jay , Talaber, Alexandra , Leong, Danielle, Dodick, David, Wethe, Jennifer, Dodick, David W. , Pang, Yi , Smith, Craig E. , Wethe, Jennifer V

Mayo Clinic

Journal of Child Neurology | October 11, 2016 | Volume: 32 | Issue: 1 | Pages: 104-111

10.1177/0883073816668704 | PMID 28257277 Get It

Efficient eye movements provide a physical foundation for proficient reading skills. We investigated the effect of in-school saccadic training on reading performance. In this cross-over design, study participants (n = 327, 165 males; mean age [SD]: 7 y 6 mo [1y 1 mo]) were randomized into treatment and control groups, who then underwent eighteen 20-minute training sessions over 5 weeks using King-Devick Reading Acceleration Program Software. Pre- and posttreatment reading assessments included fluency, comprehension, and rapid number naming performance. The treatment group had significantly greater improvement than the control group in fluency (6.2% vs 3.6%, P = .0277) and comprehension (7.5% vs 1.5%, P = .0002). The high-needs student group significantly improved in fluency ( P < .001) and comprehension ( P < .001). We hypothesize these improvements to be attributed to the repetitive practice of reading-related eye movements, shifting visuospatial attention, and visual processing. Consideration should be given to teaching the physical act of reading within the early education curriculum.
Best Practices for Monitoring Cardiac Troponin in Detecting Myocardial Injury
Apple, Fred S. , Jaffe, Allan S. , Kavsak, Peter A. , Kontos, Michael C. , Saenger, Amy K., Jaffe, Allan S. , Sharkey, Scott W. , Smith, Stephen W. , Kavsak, Peter

Mayo Clinic

Clinical Chemistry | October 6, 2016 | Volume: 63 | Issue: 1 | Pages: 37-44

10.1373/clinchem.2016.257428 | PMID 28062607 Get It

Cyclin A2 is an RNA binding protein that controls Mre11 mRNA translation
Jeganathan, Karthik B. , Limzerwala, Jazeel F. , Baker, Darren J. , Hamada, Masakazu , Nam, Hyun-Ja, Deursen, Willemijn H. van , Hamada, Naomi, Naylor, Ryan M. , Becker, Nicole A. , Davies, Brian A., Ree, Janine H. van, Mer, Georges , Maher, L. James, Katzmann, David J. , Deursen, Jan M. van , Kanakkanthara, Arun , van Deursen, Willemijn H, van Ree, Janine H, Shapiro, Virginia S, Hamada, Masakazu, Shapiro, Virginia Smith , Jeganathan, Karthik B , Baker, Darren J

Mayo Clinic

Science | September 29, 2016 | Volume: 353 | Issue: 6307 | Pages: 1549-1552

10.1126/science.aaf7463 | PMID 27708105 Get It

Cyclin A2 activates the cyclin-dependent kinases Cdk1 and Cdk2 and is expressed at elevated levels from S phase until early mitosis. We found that mutant mice that cannot elevate cyclin A2 are chromosomally unstable and tumor-prone. Underlying the chromosomal instability is a failure to up-regulate the meiotic recombination 11 (Mre11) nuclease in S phase, which leads to impaired resolution of stalled replication forks, insufficient repair of double-stranded DNA breaks, and improper segregation of sister chromosomes. Unexpectedly, cyclin A2 controlled Mre11 abundance through a C-terminal RNA binding domain that selectively and directly binds Mre11 transcripts to mediate polysome loading and translation. These data reveal cyclin A2 as a mechanistically diverse regulator of DNA replication combining multifaceted kinase-dependent functions with a kinase-independent, RNA binding–dependent role that ensures adequate repair of common replication errors.
A Randomized Phase IIb Trial of myo -Inositol in Smokers with Bronchial Dysplasia
Lam, Stephen , Mandrekar, Sumithra J. , Gesthalter, Yaron , Ziegler, Katie L. Allen, Seisler, Drew K., Midthun, David E. , Mao, Jenny T., Aubry, Marie Christine, McWilliams, Annette , Shaipanich, Tawimas , Liu, Gang , Johnson, Evan, Bild, Andrea H. , Lenburg, Marc E. , Mayo, John R. , Yi, Joanne, Tazelaar, Henry D. , Harmsen, William S. , Smith, Judith, Beane, Jennifer , Szabó, Éva , Johnson, W. Evan , Allen Ziegler, Katie L, Yi, Joanne Eunhee, Tazelaar, Henry, Limburg, Paul J. , Sin, Don D , Johnson, Evan, Ionescu, Diana N. , Tazelaar, Henry D. , Spira, Avrum , Szabo, Eva

Mayo Clinic

Cancer Prevention Research | September 22, 2016 | Volume: 9 | Issue: 12 | Pages: 906-914

10.1158/1940-6207.capr-15-0254 | PMID 27658890 Get It

Abstract Previous preclinical studies and a phase I clinical trial suggested that myo-inositol may be a safe and effective lung cancer chemopreventive agent. We conducted a randomized, double blind, placebo-controlled phase IIb study to determine the chemopreventive effects of myo-inositol in smokers with bronchial dysplasia. Smokers with ≥1 site of dysplasia identified by autofluorescence bronchoscopy-directed biopsy were randomly assigned to receive oral placebo or myo-inositol, 9 g once a day for 2 weeks, and then twice a day for 6 months. The primary endpoint was change in dysplasia rate after 6 months of intervention on a per-participant basis. Other trial endpoints reported herein include Ki-67 labeling index, blood and bronchoalveolar lavage fluid (BAL) levels of proinflammatory, oxidant/antioxidant biomarkers, and an airway epithelial gene expression signature for PI3K activity. Seventy-four (n = 38 myo-inositol and n = 36 placebo) participants with a baseline and 6-month bronchoscopy were included in all efficacy analyses. The complete response and the progressive disease rates were 26.3% versus 13.9% and 47.4% versus 33.3%, respectively, in the myo-inositol and placebo arms (P = 0.76). Compared with placebo, myo-inositol intervention significantly reduced IL6 levels in BAL over 6 months (P = 0.03). Among those with a complete response in the myo-inositol arm, there was a significant decrease in a gene expression signature reflective of PI3K activation within the cytologically normal bronchial airway epithelium (P = 0.002). The heterogeneous response to myo-inositol suggests a targeted therapy approach based on molecular alterations is needed in future clinical trials to determine the efficacy of myo-inositol as a chemopreventive agent. Cancer Prev Res; 9(12); 906–14. ©2016 AACR.